ConductScience.org, home

Gene · 5420

PODXL: podocalyxin like

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. PODXL: podocalyxin like. Genes, record 5420. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5420

On this page

Gene

Symbol
PODXL
HGNC
Name
podocalyxin like
HGNC
NCBI Gene ID
5420
NCBI Gene
HGNC ID
HGNC:9171
HGNC
Ensembl
ENSG00000128567
NCBI Gene
Aliases
Gp200, PC, PCLP, PCLP-1, PDX, PODXL1, gp135
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
O00592Podocalyxin5580Ensembl, GeneID, HGNC

Source UniProt

Patents53

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026078491 A2026-05-142O00592Espacenet
JP 2026004568 A2026-01-1458282O00592Espacenet
EP 4650780 A22025-11-1910055O00592Espacenet
US 12473600 B22025-11-182O00592Espacenet
EP 4636080 A12025-10-2218O00592Espacenet
JP 2025529142 A2025-09-043553O00592Espacenet
US 12371689 B22025-07-293553O00592Espacenet
JP 2025517970 A2025-06-1210055O00592Espacenet
US 12024722 B22024-07-02114O00592Espacenet
KR 1020240005121 A2024-01-112O00592Espacenet

1 to 10 of 53

See all 53 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,491

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitlePODXL papersNewest fiscal year
R01DK072381Kidney Injury Molecule-1 in Epithelial Repair82025
R01DK039773Mechanisms of Ischemic Kidney Injury and Repair62025
R24HD000836Laboratory of Developmental Biology52025
P30CA016672Cancer Center Support Grant42025
R01CA227942Targeting the cancer glycocalyx42025
R01DK076077Adaptive and maladaptive repair after kidney injury42025
R01HL155921Polarized Protein Trafficking and Angiogenesis42025
P30CA014520UW Comprehensive Cancer Center Support32025
P30CA016086Cancer Center Support Grant32025
P30CA022453CANCER CENTER SUPPORT GRANT32025

1 to 10 of 1,491Source NIH's project files

See all 1,491 nih grants

Papers2,215

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Kidney organoids as a platform to study plasminogen-induced injury and uPA-based therapies.Stem Cells Transl Med202642768826PubTator, text miningPubMed
A randomised controlled study of canagliflozin in improving diabetic kidney disease through a podocyte protection mechanism.Ann Acad Med Singap202642745596PubTator, text miningPubMed
Reassembly of Human Kidney Organoids after Dissociation.Nephron202642715132PubTator, text miningPubMed
Podocalyxin as biomarker for early detection of preeclampsia: A systematic review and meta-analysis.Pregnancy Hypertens202642710171PubTator, text miningPubMed
Modulating the sialic acid content of endothelial cells affects their adhesion and barrier permeability.Sci Rep202642618733PubTator, text miningPubMed
Clinical evaluation of rituximab combined with ACE inhibitors and statins in refractory nephrotic syndrome: associations with proteinuria, lipid profiles, and podocyte-related biomarkers.Front Pharmacol202642518347PubTator, text miningPubMed
Urinary podocalyxin as an early biomarker for diabetic nephropathy.PLoS One202642490553PubTator, text miningPubMed
Evaluation of serum moesin and podocalyxin levels in patients with diabetes mellitus.Open Med (Wars)202642404647PubTator, text miningPubMed
Persistent postpartum proteinuria, renal dysfunction, and future chronic kidney disease risk in women with preeclampsia.Pregnancy Hypertens202642378806PubTator, text miningPubMed
Podocalyxin may be down-regulated by progesterone in high grade serous ovarian cancer spheroids to increase responsiveness to carboplatin and NK cells.BMC Cancer202642343334PubTator, text miningPubMed

1 to 10 of 2,215

See all 2,215 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/5420

GET https://conductscience.org/api/genes/v1/5420/patents?page=2